March 13, 2018 01:06 PM EDT
Startups

An im­munother­a­py pill for pso­ri­a­sis? Es­calier gets $19M Se­ries B to tack­le R&D

Brittany Meiling

A start­up that’s hop­ing to of­fer pso­ri­a­sis pa­tients a pill to treat their con­di­tion (in­stead of the stan­dard treat­ment of steroids or in­jec­tions) has closed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times